Pharmafile Logo

Early Pipeline Case Study

- PMLiVE

Cannes Lions shows health creative is becoming an art form

If you ever want an example of art imitating life, look no further than Cannes Lions 2022. Because just like life these past two years – in fact possibly because...

- PMLiVE

EMA accepts Otsuka and Astex’s marketing authorisation application for acute myeloid leukaemia treatment 

The application is supported by results from a phase 3 trial demonstrating an exposure equivalence to the current standard of care for AML

- PMLiVE

Pfizer and BioNTech seek FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies have rapidly increased production of the newly developed vaccine and are ready to deliver doses from September

EU flag

EMA accepts Mundipharma’s application for invasive candidiasis treatment rezafungin

Despite currently available treatments, the mortality rate for patients with invasive candidiasis remains high at up to 40%

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

- PMLiVE

Moderna to supply Canada with 12 million doses of Omicron-containing bivalent COVID-19 booster

The company announced in July that it was advancing two bivalent candidates for autumn, based on different population health security strategies in different countries

- PMLiVE

Medscape: At the Heart of Education at #ESCCongress

Medscape Education Global will attend ESC from September 26-29 to host live symposia and an in-person event on key topics in cardiology.

Medscape Education

FlyPharma Europe unites pharma, biotech and bio pharma with air cargo logistics

In the middle of the pandemic, the pharma industry was under pressure to not just maintain but increase its existing business, while navigating the logistical challenges that COVID-19 placed in...

- PMLiVE

WHO recommends Valneva’s COVID-19 vaccine for those aged between 18 to 50 years old

VLA2001 is a purified, inactivated, and adjuvanted whole virus SARS-CoV-2 vaccine, employing a similar approach to the flu vaccine

- PMLiVE

EC approves Celltrion Healthcare’s Vegzelma for multiple cancer types

The biosimilar to Genentech's Avastin was found to be highly similar to the reference product

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links